LeonaBio Inc/$LONA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LeonaBio Inc
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
- Ticker
- $LONA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 19
- Headquarters
- Bothell, United States
- Website
- www.leonabio.com
LeonaBio Inc Metrics
BasicAdvanced
$37M
-
-$10.88
2.12
-
Price and volume
Market cap
$37M
Beta
2.12
52-week high
$14.21
52-week low
$2.21
Average daily volume
305K
Financial strength
Current ratio
7.011
Quick ratio
6.533
Long term debt to equity
0.003
Total debt to equity
0.017
Profitability
EBITDA (TTM)
-53.828
Management effectiveness
Return on assets (TTM)
-74.07%
Return on equity (TTM)
-431.39%
Valuation
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-0.815
Free cash flow yield (TTM)
-122.72%
Free cash flow per share (TTM)
-4.762
Growth
Earnings per share change (TTM)
-29.20%
3-year earnings per share growth (CAGR)
-27.40%
What the Analysts think about LeonaBio Inc
Analyst ratings (Buy, Hold, Sell) for LeonaBio Inc stock.
Analyst projections of the future price of LeonaBio Inc stock.
LeonaBio Inc Financial Performance
Revenues and expenses
LeonaBio Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.